The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.